Insilico Medicine, a clinical stage biotech firm that is in the process of advancing what potentially could be the world’s first generative AI-discovered and -designed drug to human clinical trials, has secured over $100 million in a fresh funding round.
Start your deal-making journey now!
Subscribe now to enjoy unlimited access at just $59.
Premium coverage on private equity, venture capital, and startups in Asia.
Exclusive scoops from our reporters in nine key markets.
In-depth interviews with industry leaders shaping the ecosystem.
Already a Subscriber? Log in
Contact us for corporate subscriptions at subs@dealstreetasia.com
